Regeneron’s DB-OTO improves hearing in two children with genetic deafness
According to the results, DB-OTO improved hearing to normal levels in the first child and showed initial hearing…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 May 24
According to the results, DB-OTO improved hearing to normal levels in the first child and showed initial hearing…
08 May 24
In the trial, Enstilar showed superiority over Daivobet ointment in meeting the primary and both secondary endpoints and…
07 May 24
Duravyu, previously known as EYP-1901, is being developed as a potential paradigm-altering therapy for individuals with VEGF-mediated retinal…
06 May 24
The results showed that BI 764524 was well received upon intravitreal administration of both single and multiple doses…
02 May 24
The CardiAMP Cell Therapy increased the exercise tolerance by 107-second and reduced angina episodes by 82% at the…
01 May 24
The positive top-line results revealed that the Phase 2/3 trial achieved its primary endpoint of improvement on the…
01 May 24
The partnership, spread across various therapeutic fields, aims to assess the use of polygenic risk scores in improving…
30 Apr 24
Enhertu demonstrated a statistically significant and clinically meaningful improvement in PFS against standard-of-care chemotherapy in the primary trial…
24 Apr 24
Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential…
25 Mar 24
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…